Engineered immune cells take on Hard-to-Treat cancers
NCT ID NCT07256756
First seen Jan 11, 2026 · Last updated Apr 28, 2026 · Updated 14 times
Summary
This early-phase study tests a new treatment called GC203 TIL for people with advanced solid tumors that no longer respond to standard therapies. The treatment uses a patient's own immune cells, which are collected from the tumor, modified in a lab to better fight cancer, and then infused back. The main goals are to check safety and see if the therapy can shrink tumors. Only 8 adults aged 18 to 75 will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.